Patents by Inventor Lewis Gazzard
Lewis Gazzard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240132507Abstract: Presently provided are inhibitors of TD02 and IDO1 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2,3 dioxygenase and indoleamine 2,3-dioxygenase 1; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.Type: ApplicationFiled: October 27, 2023Publication date: April 25, 2024Inventors: Zhonghua Pei, Brendan Parr, Wendy Liu, Richard Pastor, Lewis Gazzard, Firoz Jaipuri, Sanjeev Kumar, Hima Potturi, Guoshen Wu, Xingyu Lin, Yanyan Chu, Po-wai Yuen
-
Patent number: 11944606Abstract: Azaindole compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the azaindole compounds.Type: GrantFiled: February 17, 2021Date of Patent: April 2, 2024Assignee: Genentech, Inc.Inventors: Timothy Heffron, Sushant Malhotra, BinQing Wei, Bryan Chan, Lewis Gazzard, Emanuela Gancia, Michael Lainchbury, Andrew Madin, Eileen Seward, Yonghan Hu
-
Patent number: 11827639Abstract: Presently provided are inhibitors of TD02 and IDO1 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2,3 dioxygenase and indoleamine 2,3-dioxygenase 1; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.Type: GrantFiled: June 28, 2018Date of Patent: November 28, 2023Assignees: GENENTECH, INC., NEWLINK GENETICS CORPORATIONInventors: Zhonghua Pei, Brendan Parr, Wendy Liu, Richard Pastor, Lewis Gazzard, Firoz Jaipuri, Sanjeev Kumar, Hima Potturi, Guoshen Wu, Xingyu Lin, Yanyan Chu, Powai Yuen
-
Patent number: 11603373Abstract: Presently provided are inhibitors of cellularly expressed TD02 and IDO1, and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2,3 dioxygenase and indoleamine 2,3-dioxygenase 1; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.Type: GrantFiled: June 20, 2018Date of Patent: March 14, 2023Assignee: GENENTECH, INC.Inventors: Zhonghua Pei, Richard Pastor, Lewis Gazzard, Brendan Parr, Wendy Liu, Rohan Mendonca, Guosheng Wu, Po-wai Yuen
-
Patent number: 11566003Abstract: Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.Type: GrantFiled: July 6, 2020Date of Patent: January 31, 2023Assignee: Genentech, Inc.Inventors: Bryan Chan, Joy Drobnick, Lewis Gazzard, Timothy Heffron, Jun Liang, Sushant Malhotra, Rohan Mendonca, Naomi Rajapaksa, Craig Stivala, John Tellis, Weiru Wang, BinQing Wei, Aihe Zhou, Matthew W. Cartwright, Michael Lainchbury, Emanuela Gancia, Eileen Seward, Andrew Madin, David Favor, Kin Chiu Fong, Yonghan Hu, Andrew Good
-
Publication number: 20220306635Abstract: Presently provided are inhibitors of cellularly expressed TD02 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.Type: ApplicationFiled: October 12, 2020Publication date: September 29, 2022Inventors: Xingyu Lin, Po-wai Yuen, Rohan Mendonca, Brendan Parr, Richard Pastor, Zhonghua Pei, Lewis Gazzard, Firoz Jaipuri, Sanjeev Kumar, Xiaokai Li, Roheeth Pavana, Hima Potturi, Venkata Velvadapu, Jesse Waldo, Zuhui Zhang, Guosheng Wu, Benjamin Douglas Sellers
-
Publication number: 20210299110Abstract: Azaindole compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the azaindole compounds.Type: ApplicationFiled: February 17, 2021Publication date: September 30, 2021Applicant: Genentech, Inc.Inventors: Timothy HEFFRON, Sushant MALHOTRA, BinQing WEI, Bryan CHAN, Lewis GAZZARD, Emanuela GANCIA, Michael LAINCHBURY, Andrew MADIN, Eileen SEWARD, Yonghan HU
-
Patent number: 11034692Abstract: Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.Type: GrantFiled: August 15, 2019Date of Patent: June 15, 2021Assignee: Genentech, Inc.Inventors: Bryan Chan, Blake Daniels, Joy Drobnick, Lewis Gazzard, Timothy Heffron, Malcolm Huestis, Jun Liang, Sushant Malhotra, Rohan Mendonca, Naomi Rajapaksa, Michael Siu, Craig Stivala, John Tellis, Weiru Wang, BinQing Wei, Aihe Zhou, Matthew W. Cartwright, Emanuela Gancia, Graham Jones, Michael Lainchbury, Andrew Madin, Eileen Seward, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu, Baihua Hu, Aijun Lu
-
Publication number: 20210163417Abstract: Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.Type: ApplicationFiled: July 6, 2020Publication date: June 3, 2021Applicant: Genentech, Inc.Inventors: Bryan Chan, Joy Drobnick, Lewis Gazzard, Timothy Heffron, Jun Liang, Sushant Malhotra, Rohan Mendonca, Naomi Rajapaksa, Craig Stivala, John Tellis, Weiru Wang, BinQing Wei, Aihe Zhou, Matthew W. Cartwright, Michael Lainchbury, Emanuela Gancia, Eileen Seward, Andrew Madin, David Favor, Kin Chiu Fong, Yonghan Hu, Andrew Good
-
Patent number: 10952995Abstract: Azaindole compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the azaindole compounds.Type: GrantFiled: September 12, 2019Date of Patent: March 23, 2021Assignee: Genentech, Inc.Inventors: Timothy Heffron, Sushant Malhotra, BinQing Wei, Bryan Chan, Lewis Gazzard, Emanuela Gancia, Michael Lainchbury, Andrew Madin, Eileen Seward, Yonghan Hu
-
Patent number: 10800780Abstract: Presently provided are inhibitors of cellularly expressed TDO2 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.Type: GrantFiled: December 23, 2016Date of Patent: October 13, 2020Assignees: Genentech, Inc., NewLink Genetics CorporationInventors: Xingyu Lin, Po-wai Yuen, Rohan Mendonca, Brendan Parr, Richard Pastor, Zhonghua Pei, Lewis Gazzard, Firoz Jaipuri, Sanjeev Kumar, Xiaokai Li, Roheeth Pavana, Hima Potturi, Venkata Velvadapu, Jesse Waldo, Zuhui Zhang, Guosheng Wu, Benjamin Douglas Sellers
-
Patent number: 10766903Abstract: The present invention concerns the identification of inhibitors of ubiquitin specific protease 7 (USP7), and methods of use thereof.Type: GrantFiled: October 20, 2017Date of Patent: September 8, 2020Assignee: ALMAC DISCOVERY LIMITEDInventors: Colin O'Dowd, Tim Harrison, Peter Hewitt, Shane Rountree, Miel Hugues, Frank Burkamp, Linda Duncan Jordan, Matthew Helm, Fabio Broccatelli, James John Crawford, Lewis Gazzard, Ingrid Wertz, Wendy Lee
-
Publication number: 20200216456Abstract: Presently provided are inhibitors of TD02 and IDOl and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2,3 dioxygenase and indoleamine 2,3-dioxygenase 1; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.Type: ApplicationFiled: June 28, 2018Publication date: July 9, 2020Inventors: Zhonghua Pei, Brendan Parr, Wendy Liu, Richard Pastor, Lewis Gazzard, Firoz Jaipuri, Sanjeev Kumar, Hima Potturi, Guoshen Wu, Xingyu Lin, Yanyan Chu, Powai Yuen
-
Publication number: 20200123163Abstract: Presently provided are inhibitors of cellularly expressed TD02 and IDO1, and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2,3 dioxygenase and indoleamine 2,3-dioxygenase 1; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.Type: ApplicationFiled: June 20, 2018Publication date: April 23, 2020Inventors: Zhonghua Pei, Richard Pastor, Lewis Gazzard, Brendan Parr, Wendy Liu, Rohan Mendonca, Guosheng WU, Po-wai Yuen
-
Publication number: 20200000780Abstract: Azaindole compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the azaindole compounds.Type: ApplicationFiled: September 12, 2019Publication date: January 2, 2020Applicant: Genentech, Inc.Inventors: Timothy HEFFRON, Sushant MALHOTRA, BinQing WEI, Bryan CHAN, Lewis GAZZARD, Emanuela GANCIA, Michael LAINCHBURY, Andrew MADIN, Eileen SEWARD, Yonghan HU
-
Patent number: 10407424Abstract: Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.Type: GrantFiled: March 30, 2018Date of Patent: September 10, 2019Assignee: Genentech, Inc.Inventors: Bryan Chan, Naomi Rajapaksa, Michael Siu, Craig Stivala, John Tellis, Weiru Wang, BinQing Wei, Aihe Zhou, Matthew W. Cartwright, Emanuela Gancia, Graham Jones, Blake Daniels, Michael Lainchbury, Andrew Madin, Eileen Seward, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu, Baihua Hu, Aijun Lu, Joy Drobnick, Lewis Gazzard, Timothy Heffron, Malcolm Huestis, Jun Liang, Sushant Malhotra, Rohan Mendonca
-
Publication number: 20190256518Abstract: The present invention concerns the identification of inhibitors of ubiquitin specific protease 7 (USP7), and methods of use thereof.Type: ApplicationFiled: October 20, 2017Publication date: August 22, 2019Inventors: Colin O'DOWD, Tim HARRISON, Peter HEWITT, Shane ROUNTREE, Miel HUGUES, Frank BURKAMP, Linda Duncan JORDAN, Matthew HELM, Fabio BROCCATELLI, James John CRAWFORD, Lewis GAZZARD, Ingrid WERTZ, Wendy LEE
-
Publication number: 20190016726Abstract: Presently provided are inhibitors of cellularly expressed TDO2 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.Type: ApplicationFiled: December 23, 2016Publication date: January 17, 2019Inventors: Xingyu Lin, Po-wai Yuen, Rohan Mendonca, Brendan Parr, Richard Pastor, Zhonghua Pei, Lewis Gazzard, Firoz Jaipuri, Sanjeev Kumar, Xiaokai Li, Roheeth Pavana, Hima Potturi, Venkata Velvadapu, Jesse Waldo, Zuhui Zhang, Guosheng Wu
-
Patent number: 10154995Abstract: Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.Type: GrantFiled: August 23, 2017Date of Patent: December 18, 2018Assignees: Array BioPharma Inc., Genentech, Inc.Inventors: James F. Blake, Adam Cook, Indrani W. Gunawardana, Kevin W. Hunt, Michael Lyon, Andrew T. Metcalf, Peter J. Mohr, David A. Moreno, Brad Newhouse, Li Ren, Tony P. Tang, Allen A. Thomas, Jacob Schwarz, Jane Schmidt, Lewis Gazzard, Huifen Chen
-
Publication number: 20180282282Abstract: Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibitng HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.Type: ApplicationFiled: March 30, 2018Publication date: October 4, 2018Applicant: Genentech, Inc.Inventors: Bryan Chan, Joy Drobnick, Lewis Gazzard, Timothy Heffron, Jun Liang, Sushant Malhotra, Rohan Mendonca, Naomi Rajapaksa, Craig Stivala, John Tellis, Weiru Wang, BinQing Wei, Aihe Zhou, Matthew W. Cartwright, Michael Lainchbury, Emanuela Gancia, Eileen Seward, Andrew Madin, David Favor, Kin Chiu Fong, Yonghan Hu, Andrew Good